NCT03743376View on ClinicalTrials.gov

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

October 15, 2020

Study Completion Date

December 31, 2021

Conditions
HIV-1 Infection
Interventions
BIOLOGICAL

UB-421(25 mg/kg) Q2W

Monoclonal antibody by IV infusion plus standard ART

BIOLOGICAL

UB-421(25 mg/kg) Q4W

Monoclonal antibody by IV infusion plus standard ART

Trial Locations (3)

201

Taipei Veterans General Hospital, Taipei

Unknown

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Kaohsiung Veterans General Hospital, Kaohsiung City

Sponsors

Lead Sponsor

United BioPharma
All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Taoyuan General Hospital

OTHER_GOV

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

collaborator

Kaohsiung Veterans General Hospital.

OTHER

lead

United BioPharma

INDUSTRY

NCT03743376 - The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients | Biotech Hunter | Biotech Hunter